Advocacy intelligence hub — real-time data for patient organizations
Alliance for Clinical Trials in Oncology — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
CYRAMZA
(ramucirumab)Orphan drugEli Lilly and Company
Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]
12.1 Mechanism of Action Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VE...
Enhertu
(fam-trastuzumab deruxtecan-nxki)Orphan drugstandardDaiichi Sankyo, Inc.
12.1 Mechanism of Action Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate. The antibody is a humanized anti-HER2 IgG1. The s...
James Yao
M.D. Anderson Cancer Center
Luigi Ricciardiello, MD, DMD
Associate Professor of Gastroenterology, University of Bologna
📍 LACONIA, NH
Andrew M Blakely, M.D., STNA
National Cancer Institute (NCI)
📍 COLUMBUS, OH
Bryson W Katona, MD, PhD
University of Pennsylvania
📍 PHILADELPHIA, PA
Raymond Kim, MD
University Health Network, Toronto
Massimiliano di Pietro, MD
MRC Cancer Unit.University of Cambridge.